Understanding how FGF21 affects bone health in Duchenne Muscular Dystrophy
Investigating the role of FGF21 in bone homeostasis in Duchenne Muscular Dystrophy
This study is looking at how a protein called FGF21 might help keep bones healthy for people with Duchenne Muscular Dystrophy (DMD), which can cause muscle loss and bone problems, and it aims to find new ways to prevent bone loss in these patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11161782 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called FGF21 in maintaining bone health for patients with Duchenne Muscular Dystrophy (DMD), a condition that leads to muscle loss and often results in severe bone issues. The study will use mouse models to explore how FGF21 influences the cells responsible for bone breakdown, known as osteoclasts, and how it may contribute to osteoporosis in DMD. By understanding the mechanisms behind FGF21's effects, researchers hope to identify potential treatments to prevent bone loss in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne Muscular Dystrophy who are experiencing or at risk for osteoporosis.
Not a fit: Patients without Duchenne Muscular Dystrophy or those who do not have bone health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help prevent bone loss and fractures in patients with Duchenne Muscular Dystrophy.
How similar studies have performed: While the specific role of FGF21 in DMD is being explored, similar research has shown promise in understanding bone health in other conditions, suggesting potential for success in this novel approach.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Hurley-Novatny, Amelia Charlotte — University of Iowa
- Study coordinator: Hurley-Novatny, Amelia Charlotte
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.